PRMT6.2 Antibody

What is PRMT6 and what cellular functions make it important for research?

PRMT6 is a type I protein arginine methyltransferase that catalyzes the asymmetric dimethylation of arginine residues. It plays a pivotal role in regulating transcription by methylating histone H3 at arginine 2 (H3R2), which generally suppresses gene expression . PRMT6 is predominantly nuclear and contributes to several cellular processes including:

• Transcriptional regulation through histone modification

• DNA repair processes through modification of DNA polymerase β

• Cell cycle regulation and proliferation control

• Inhibition of viral transcription through methylation of proteins like HIV Tat

PRMT6 is overexpressed in several cancer types including breast, cervix, bladder, prostate, and lung cancer, suggesting its importance in tumor development and progression .

Proper validation of PRMT6 antibodies should include:

• Positive and negative controls

  • Use cell lines with known PRMT6 expression (e.g., HeLa cells)

  • Compare with PRMT6 knockdown/knockout samples using siRNA or shRNA

• Western blot verification

  • Confirm single band at expected molecular weight (41-42 kDa)

  • Test dilution series to determine optimal concentration

• Cross-reactivity assessment

  • Test in multiple species if cross-species reactivity is claimed

  • Commercial antibodies show varying reactivity patterns with human, mouse, and rat samples

• Application-specific validation

  • For ChIP applications, verify enrichment at known PRMT6 target genes

  • For IHC, include appropriate tissue controls

Always include isotype-matched IgG controls for immunoprecipitation and ChIP experiments to assess non-specific binding .

What are the key differences between monoclonal and polyclonal PRMT6 antibodies?

For detecting low abundance PRMT6, polyclonal antibodies may offer better sensitivity. For applications requiring high specificity, particularly distinguishing PRMT6 from other PRMT family members, monoclonal antibodies are often preferred .

What epitopes are typically targeted by commercial PRMT6 antibodies?

Commercial PRMT6 antibodies target various regions:

• N-terminal region (AA 19-48)

• C-terminal region (AA 301-375)

• Internal regions

• Full-length recombinant protein

Some antibodies are specifically designed to target synthetic peptides within human PRMT6, while others are generated against recombinant full-length protein . The epitope location can affect antibody performance in specific applications - C-terminal antibodies may perform differently in applications where the C-terminus is involved in protein interactions.

How should researchers optimize PRMT6 ChIP experiments?

Optimizing PRMT6 ChIP experiments requires attention to several key parameters:

• Cross-linking conditions

  • Use 1% formaldehyde for 10 minutes as starting point

  • Adjust based on chromatin accessibility and antibody performance

• Chromatin fragmentation

  • Aim for DNA fragments of 200-500 bp

  • Optimize sonication conditions for your specific cell type

• Antibody selection and amount

  • Use ChIP-validated PRMT6 antibodies

  • Typically 5 μg of antibody per ChIP reaction is suitable

• Controls

  • Include IgG negative control

  • Use PRMT6 knockdown cells as specificity control

  • Include H3R2me2a ChIP as functional validation

• Validation by qPCR

  • Design primers for known PRMT6 target regions

  • Compare enrichment between target and non-target regions

Research shows that PRMT6 often co-localizes with H3R2me2a marks, and ChIP-reChIP experiments (sequential ChIP with PRMT6 followed by H3R2me2a antibodies) can confirm this association .

What controls are essential when studying PRMT6-mediated methylation?

When investigating PRMT6-mediated methylation, include these controls:

• Antibody controls

  • Isotype-matched IgG as negative control

  • Pre-blocking antibody with immunizing peptide

• Genetic controls

  • PRMT6 knockdown using shRNA or siRNA

  • PRMT6 overexpression systems

• Enzymatic controls

  • Use PRMT6 inhibitors (e.g., EPZ020411)

  • Include catalytically inactive PRMT6 mutants

• Substrate controls

  • Include non-substrate proteins

  • Use arginine-to-lysine mutant versions of substrates

• Methylation-specific controls

  • Verify methylation using anti-methylarginine antibodies

  • Perform mass spectrometry to confirm methylation sites

For methylation assays, in vitro methylation using recombinant PRMT6 and S-adenosyl-methionine (AdoMet) as methyl donor can provide a positive control for antibody specificity .

How can researchers distinguish between PRMT6 and other PRMT family members?

Distinguishing PRMT6 from other PRMTs requires careful experimental design:

• Antibody selection

  • Choose antibodies raised against non-conserved regions of PRMT6

  • Verify antibody specificity against recombinant PRMT proteins

• Western blot analysis

  • PRMT6 has a molecular weight of approximately 41-42 kDa

  • Compare molecular weights with other PRMTs

  • Perform side-by-side comparisons with antibodies against different PRMTs

• Substrate specificity

  • PRMT6 preferentially methylates H3R2

  • PRMT6 recognizes RG motifs rather than RGG motifs common for other PRMTs

  • PRMT6 has a preference for basic and bulky residues adjacent to methylation sites

• Knockdown validation

  • Perform parallel knockdowns of different PRMTs

  • Compare effects on substrate methylation

Research shows that PRMT6 has a distinctive substrate recognition pattern, preferring the RG motif rather than the RGG motif that is recognized by some other PRMTs . This difference can be exploited to distinguish PRMT6-specific activity.

What methods should be used to assess PRMT6 activity versus protein levels?

Different methodological approaches are required to distinguish between PRMT6 activity and protein levels:

When assessing PRMT6 activity, remember that:

• H3R2me2a levels don't always directly correlate with PRMT6 protein levels

• Other factors may influence PRMT6 activity, including post-translational modifications

• PRMT6 activity may be substrate-specific in different cellular contexts

How do PRMT6 expression levels correlate with DNA methylation patterns?

Research has revealed interesting relationships between PRMT6 expression and DNA methylation:

• Inverse correlation with global methylation

  • Cancer cell lines with high PRMT6 expression show lower levels of 5mC

  • This pattern is observed in lung cancer and colorectal cancer patient samples

• UHRF1-dependent relationship

  • The inverse correlation between PRMT6 and DNA methylation may depend on UHRF1 expression levels

  • Samples should be stratified based on UHRF1 expression for meaningful analysis

• Methodological approach

  • Use PRMT6 antibodies for protein expression quantification

  • Measure 5mC levels using LC-MS/MS or immunoassays

  • For clinical samples, analyze the correlation between samples with highest vs. lowest 20% of PRMT6 expression

When investigating this relationship, consider that:

• The correlation varies between cancer types (stronger in lung and colorectal cancers than in breast cancer)

• PRMT6 upregulation affects DNA methylation patterns through complex mechanisms

• Both PRMT6 and DNA methylation levels show high variability within cancer types

What is known about PRMT6 antibody performance in glioblastoma research?

Recent studies investigating PRMT6 in glioblastoma provide insights into antibody applications:

• Expression patterns

  • PRMT6 is highly expressed in mesenchymal subtype or invasive gliomas

  • Expression levels negatively correlate with patient prognosis

• Functional investigations

  • PRMT6 promotes invasion and migration in glioblastoma cells

  • Inhibition using PRMT6 shRNA or EPZ020411 inhibitor reduces invasion and migration

• Immunohistochemical applications

  • PRMT6 antibodies can detect expression in both cell lines and tissue sections

  • IHC staining of mouse brain tumor sections is effective for visualizing PRMT6 expression

  • Can be used to assess relationships between PRMT6, TRAF6, and EZH2 in tumor sections

• Experimental considerations

  • Include appropriate controls (PRMT6 knockdown/inhibition)

  • Correlate with H3R2me2a levels as functional readout

  • Consider dual immunofluorescence with invasion markers

What approaches work best for detecting PRMT6 in embryonic stem cells?

PRMT6 plays roles in embryonic stem (ES) cell self-renewal and differentiation. When working with ES cells:

• Antibody selection and validation

  • Verify antibody reactivity in mouse ES cells

  • Use PRMT6 knockdown ES cells as negative control

• ChIP protocol optimization

  • ES cells may require modified cross-linking conditions

  • ChIP with anti-PRMT6 antibody can identify genomic targets

  • Correlate with H3R2me2a, H3K4me3, and H3K4me2 ChIP data

• Differentiation studies

  • Monitor PRMT6 expression during embryoid body formation

  • Track correlation between PRMT6 levels and pluripotency/differentiation markers

• Technical considerations

  • For Western blotting of ES cells, load 15-50 μg protein per lane

  • For ChIP-qPCR, design primers for ES cell-specific PRMT6 target genes

  • When studying differentiation, collect samples at multiple time points during embryoid body formation

How can researchers study PRMT6 substrate specificity?

PRMT6 has distinctive substrate specificity that can be studied using these approaches:

• Peptide-based approaches

  • PRMT6 has broad specificity but prefers basic and bulky residues near methylation sites

  • PRMT6 recognizes the RG motif rather than RGG motifs preferred by other PRMTs

  • Use synthetic peptide arrays with systematic amino acid substitutions to assess preference

• Protein substrate studies

  • PRMT6 methylates histones, particularly H3R2 and to a lesser extent H3R8

  • It can also methylate H4R3, showing preference for RG motifs

  • Use in vitro methylation assays with recombinant proteins followed by mass spectrometry

• Methodological workflow

  • Express and purify recombinant PRMT6

  • Perform in vitro methylation with AdoMet

  • Analyze methylated products using mass spectrometry

  • Validate with methylarginine-specific antibodies

For quantitative assessment of PRMT6 substrate specificity, mass spectrometry with targeted methods can measure the effect of amino acid substitutions on methylation efficiency at specific arginine residues .

What are the recommended methods for studying PRMT6 in cancer?

PRMT6 is overexpressed in several cancer types and studying its role requires specific methodological approaches:

• Expression analysis

  • IHC can assess PRMT6 expression in tumor tissue sections

  • Western blotting quantifies expression in cancer cell lines

  • Consider correlation with cancer stem cell markers

• Functional studies

  • Use shRNA or siRNA for knockdown studies

  • PRMT6 inhibitors like EPZ020411 can be used for pharmacological inhibition

  • Monitor effects on proliferation, cell cycle, and senescence

• Mechanistic investigations

  • ChIP-seq to identify PRMT6 genomic targets in cancer cells

  • Study correlation with H3R2me2a levels

  • Investigate interaction with cancer-related proteins

• Clinical correlations

  • Analyze TCGA data for correlations between PRMT6 expression and clinical parameters

  • Stratify samples by PRMT6 expression levels (highest vs. lowest 20%)

  • Assess relationship with DNA methylation patterns

PRMT6 has been linked to regulation of specific tumor suppressor genes like p21 (CDKN1A), making it a potential target for cancer therapy .

What technical challenges exist with current PRMT6 antibodies?

Researchers should be aware of these technical limitations:

• Cross-reactivity issues

  • Some antibodies may cross-react with other PRMT family members

  • Validate specificity using PRMT6 knockdown controls

• Epitope accessibility

  • Post-translational modifications may affect antibody recognition

  • Protein-protein interactions might mask epitopes

• Application-specific limitations

  • Not all antibodies work equally well for all applications

  • ChIP-grade antibodies require additional validation

  • Flow cytometry applications may require specific clones

• Species reactivity

  • Many antibodies are validated only for human PRMT6

  • Careful validation is needed when using in other species

  • Some antibodies show reactivity with rat, mouse, and other species based on sequence homology

• Detection sensitivity

  • Low expression levels may require signal amplification techniques

  • Consider using more sensitive detection methods for tissues with low PRMT6 expression